Early outcomes following EndoFLIP-tailored peroral endoscopic myotomy (POEM): the establishment of POEM services in two UK centers
Diseases of the Esophagus · 2023
DOI: 10.1093/dote/doac110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, 2023. Verfasst von William Knight und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nottingham University Hospital, Nottingham, UK. Hauptthemen laut MEDLINE: Natural Orifice Endoscopic Surgery, Esophageal Achalasia, Gastroesophageal Reflux, Myotomy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Peroral endoscopic myotomy (POEM) is a safe and effective minimally invasive treatment for achalasia. Postoperative reflux rates remain high. The functional luminal imaging probe (FLIP) allows intraoperative measurement of lower esophageal distensibility during POEM. In theory, this enables a tailoring of myotomies to ensure adequate distensibility while minimizing postoperative reflux risk. Two prospectively collected POEM databases were analyzed from two UK tertiary upper GI centers. The operators in each center used FLIP measurements to ensure adequate myotomy. Outcome measures included Eckardt score (where <3 indicated clinical success) and proton-pump inhibitor use (PPI), collected at the first postoperative appointment. Length of stay was recorded as were complications. In all, 142 patients underwent POEM between 2015 and 2019. Overall, 90% (128/142) had postoperative Eckardt scores of <3 at 6 weeks. Clinical success improved to 93% (66/71) in the latter half of each series with a significantly higher rate of complete symptom resolution (53 versus 26%, P = 0.003). In all, 79% of the poor responders had previous interventions compared with 55% of responders (P = 0.09). Median post-myotomy distensibility index was 4.0 mm2/mmHg in responders and 2.9 in nonresponders (P = 0.16). Myotomy length of <7 cm was associated with 93% clinical success and 40% post op PPI use compared with 60% PPI use with longer myotomies. There were two type IIIa, two type IIIb, and one IV Clavien–Dindo complications. This is the largest series of endoluminal functional lumen imaging probe (EndoFLIP)-tailored POEM in the UK to date. The shorter myotomies, allowed through EndoFLIP tailoring, remained clinically effective at 6 weeks. Complete symptom response rates improved in the latter half of each series. More data will be needed from high-volume collaborations to decipher optimal myotomy profiles based on EndoFLIP parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Nottingham University Hospital, Nottingham, UK.
- Guy's and St Thomas' Hospitals, London, UK.
- University Hospital Coventry and Warwickshire, Coventry, UK.
- NIHR Nottingham Digestive Diseases Centre, Nottingham University Hospital NHS Trust, Nottingham, UK.
- King's College London Medical School, London, UK.
Zitieren
APA
Knight, W., Kandiah, K., Vrakopoulou, Z., White, A., Barbieri, L., Tewari, N., Couch, J., DiMaggio, F., Barley, M., Ragunath, K., Catton, J., & Botha, A. (2023). Early outcomes following EndoFLIP-tailored peroral endoscopic myotomy (POEM): the establishment of POEM services in two UK centers. Diseases of the Esophagus. https://doi.org/10.1093/dote/doac110
Vancouver
Knight W, Kandiah K, Vrakopoulou Z, White A, Barbieri L, Tewari N, et al. Early outcomes following EndoFLIP-tailored peroral endoscopic myotomy (POEM): the establishment of POEM services in two UK centers. Diseases of the Esophagus. 2023. doi:10.1093/dote/doac110
BibTeX
@article{Knight2023,
author = {Knight, William and Kandiah, Kaveetha and Vrakopoulou, Zoi and White, Annabel and Barbieri, Lavinia and Tewari, Nilanjana and Couch, Jennifer and DiMaggio, Francesco and Barley, Mark and Ragunath, Krish and Catton, James and Botha, Abraham},
title = {Early outcomes following EndoFLIP-tailored peroral endoscopic myotomy (POEM): the establishment of POEM services in two UK centers},
journal = {Diseases of the Esophagus},
year = {2023},
doi = {10.1093/dote/doac110}
}
EUVIMED